Fibrinolysis and hemorheology in chronic venous insufficiency: a double blind study of troxerutin efficiency.
Abnormal increase of erythrocyte aggregation and reduction of profibrinolytic activity are the two most frequent biological perturbations found in chronic venous insufficiency (CVI). A randomised, controlled, double blind trial was undertaken on 85 patients suffering from grade 1 and 2 CVI, to compare troxerutin with placebo. Two types of biological parameters were measured after 15 days of treatment. Erythrocyte aggregation as evaluated with a Myrenne erythroaggregometer by the indices M (stasis) and M1 (3s-1) progressed favorably in the troxerutin group. The values of M1 at D15 (p < 0.05), and the progression of M (p < 0.001) and M1 (p < 0.01) from D0 to D15, are significantly better in the troxerutin group. Progression of fibrinolytic activity at rest was not significantly different between the 2 groups. Conversely, the progression from D0 to D15 of the values after occlusion of euglobulin lysis time (p < 0.01), tPA (p < 0.01), and PAI activity (p < 0.05) are significantly better in the troxerutin group. The fibrinolysis capacity estimated by euglobulin lysis time (p < 0.01) and tPA (p < 0.05) also progressed favorably in the troxerutin group. These results confirm the anti-erythrocyte aggregation effect of troxerutin, and suggest a favorable effect on blood fibrinolytic activity. They could explain the positive action of this drug on stasis, capillary perfusion and trophic complications of CVL.
Boisseau
M R
MR
Laboratoire d'Hématologie, Université de Bordeaux II, Pessac, France.
Taccoen
A
A
Garreau
C
C
Vergnes
C
C
Roudaut
M F
MF
Garreau-Gomez
B
B
D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D002908:Chronic Disease; D004311:Double-Blind Method; D005260:Female; D005342:Fibrinolysis; D018056:Hemorheology; D006801:Humans; D006896:Hydroxyethylrutoside / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010919:Placebos; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*; D014689:Venous Insufficiency / Q000188:drug therapy* / Q000503:physiopathology*
D000925:Anticoagulants; D006896:Hydroxyethylrutoside; D010919:Placebos; D014662:Vasoconstrictor Agents; C005865:troxerutin